Evaluating response to neoadjuvant therapy requires a holistic multimodal approach. This session focuses on interpreting baseline and follow-up studies, recognizing residual disease, and distinguishing viable tumor from treatment effects. You’ll review a carefully curated cases collection and learn to avoid common interpretation pitfalls.

• Identify imaging features of treatment response and residual disease
• Differentiate fibrosis from residual tumor across different modalities
  
• Understand the role and limitations of mammography, ultrasound, and MRI
  
• Avoid typical pitfalls and select the most suitable imaging tools